Penbrook Management LLC Boosts Stock Position in CryoPort, Inc. $CYRX

Penbrook Management LLC increased its position in shares of CryoPort, Inc. (NASDAQ:CYRX) by 251.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,775 shares of the company’s stock after acquiring an additional 132,940 shares during the period. CryoPort comprises 1.2% of Penbrook Management LLC’s investment portfolio, making the stock its 22nd biggest position. Penbrook Management LLC’s holdings in CryoPort were worth $1,538,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in CryoPort by 285.5% during the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after purchasing an additional 194,482 shares during the period. Creative Planning acquired a new position in shares of CryoPort in the second quarter valued at approximately $96,000. Rhumbline Advisers increased its stake in CryoPort by 17.6% during the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock worth $687,000 after buying an additional 13,778 shares during the period. American Century Companies Inc. lifted its holdings in CryoPort by 24.4% during the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock worth $663,000 after buying an additional 17,459 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in CryoPort in the 2nd quarter valued at approximately $254,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at CryoPort

In related news, CFO Robert Stefanovich sold 169,427 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the sale, the chief financial officer owned 109,850 shares in the company, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ramkumar Mandalam sold 23,214 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $15.44, for a total value of $358,424.16. Following the completion of the transaction, the director directly owned 67,894 shares of the company’s stock, valued at $1,048,283.36. This trade represents a 25.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 227,641 shares of company stock valued at $3,622,515. 10.00% of the stock is currently owned by corporate insiders.

CryoPort Trading Up 2.3%

Shares of CYRX opened at $15.88 on Friday. The firm has a market capitalization of $800.38 million, a price-to-earnings ratio of 11.76 and a beta of 1.90. The firm’s fifty day simple moving average is $13.44 and its 200-day simple moving average is $10.69. CryoPort, Inc. has a twelve month low of $6.69 and a twelve month high of $16.73.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. On average, analysts predict that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CYRX. Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Jefferies Financial Group set a $13.50 price target on CryoPort in a report on Monday, June 8th. Needham & Company LLC increased their price target on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. KeyCorp lifted their price objective on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Finally, Guggenheim boosted their price objective on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.11.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.